Mostrando 3 resultados de: 3
A-ring modified steroidal azoles retaining similar potent and slowly reversible CYP17A1 inhibition as abiraterone
ArticleAbstract: Abiraterone acetate is a potent inhibitor of human cytochrome P450c17 (CYP17A1, 17α-hydroxylase/17,2Palabras claves:abiraterone, androgen, CYP17A1, Cytochrome p450, Enzymology, Prostate cancer, steroidogenesisAutores:Bratoeff E., Garrido M., Peng H.M., Richard J. Auchus, Upadhyay S.K., Yoshimoto F.K.Fuentes:scopusHuman cytochrome P450 17A1 structures with metabolites of prostate cancer drug abiraterone reveal substrate-binding plasticity and a second binding site
ArticleAbstract: Abiraterone acetate is a first-line therapy for castration-resistant prostate cancer. This prodrug iPalabras claves:abiraterone, abiraterone metabolism, CYP17A1, Cytochrome p450, Prostate cancer, steroidogenesisAutores:Bart A.G., Peng H.M., Petrunak E.M., Richard J. Auchus, Scott E.E.Fuentes:scopusSelectivity of osilodrostat as an inhibitor of human steroidogenic cytochromes P450
ArticleAbstract: Osilodrostat (LCI699) is a potent inhibitor of the human steroidogenic cytochromes P450 11β-hydroxylPalabras claves:Cushing syndrome, Cytochrome p450, LCI699, Osilodrostat, steroidogenesisAutores:Liu J., Oommen J., Peng H.M., Richard J. Auchus, Valentín-Goyco J.Fuentes:scopus